StockNews.com Initiates Coverage on Cara Therapeutics (NASDAQ:CARA)

Equities researchers at StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Performance

Shares of NASDAQ CARA opened at $0.27 on Friday. Cara Therapeutics has a 1 year low of $0.24 and a 1 year high of $1.41. The stock’s 50-day simple moving average is $0.30 and its 200-day simple moving average is $0.46. The firm has a market cap of $14.49 million, a price-to-earnings ratio of -0.12 and a beta of 0.70.

Cara Therapeutics (NASDAQ:CARA) last issued its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The business had revenue of $0.99 million for the quarter, compared to analyst estimates of $1.26 million. As a group, research analysts predict that Cara Therapeutics will post -1.24 EPS for the current year.

Institutional Trading of Cara Therapeutics

An institutional investor recently bought a new position in Cara Therapeutics stock. Marquette Asset Management LLC bought a new position in Cara Therapeutics, Inc. (NASDAQ:CARA) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 94,238 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Marquette Asset Management LLC owned about 0.17% of Cara Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.